Navigation Links
Antifolate in Medical News

Novel treatments show improvements in survival and response rates for leukemia and lymphoma

...treatment regimens, including an autologous stem cell transplant for some patients. Designed to be selectively transported into tumor cells, the novel antifolate pralatrexate accumulates to high concentrations in the tumor cell, inhibiting DNA synthesis. A total of 115 patients were enrolled into this phase ...

Novel Treatments Demonstrate Improvements in Overall Survival and Response Rates in Difficult-To-Treat Forms of Leukemia and Lymphoma

...treatment regimens, including an autologous stem cell transplant for some patients. Designed to be selectively transported into tumor cells, the novel antifolate pralatrexate accumulates to high concentrations in the tumor cell, inhibiting DNA synthesis. A total of 115 patients were enrolled into this ...

Allos Therapeutics Appoints Bruce K. Bennett as Vice President, Manufacturing

...and commercialization of small molecule therapeutics for the treatment of cancer. The Company's lead product candidate, PDX (pralatrexate), is a novel antifolate currently under evaluation in a pivotal Phase 2 (PROPEL) trial in patients with relapsed or refractory peripheral T-cell lymphoma. The PROPEL trial is...

Allos Therapeutics to Present at the 2007 RBC Capital Markets Healthcare Conference

...and commercialization of small molecule therapeutics for the treatment of cancer. The Company's lead product candidate, PDX (pralatrexate), is a novel antifolate currently under evaluation in a pivotal Phase 2 (PROPEL) trial in patients with relapsed or refractory peripheral T-cell lymphoma. The PROPEL trial is...

Allos Therapeutics Reports Third Quarter 2007 Financial Results

...and commercialization of small molecule therapeutics for the treatment of cancer. The Company's lead product candidate, PDX (pralatrexate), is a novel antifolate currently under evaluation in a pivotal Phase 2 (PROPEL) trial in patients with relapsed or refractory peripheral T-cell lymphoma. The PROPEL trial is...

Allos Therapeutics to Present at the 2007 Acumen BioFin Rodman & Renshaw Conference

...and commercialization of small molecule therapeutics for the treatment of cancer. The Company's lead product candidate, PDX (pralatrexate), is a novel antifolate currently under evaluation in a pivotal Phase 2 (PROPEL) trial in patients with relapsed or refractory peripheral T-cell lymphoma. The PROPEL trial is...

Antifolate Drugs may Be Effective in Treating P Vivax Malaria

...Malaria and Leishmaniasis Control Programme in Pakistan, have revealed that antifolate drugs may be effective in treating P vivax malaria. Toby Leslie, M.Sc., and colleagues tested the relative efficacy and safety of two antifolate drugs (sulfadoxine-pyrimethamine and chlorproguanil-dapsone) against P viva...
Antifolate in Medical Technology

Interim Safety Analysis Supports Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma

...and commercialization of small molecule therapeutics for the treatment of cancer. The Company's lead product candidate, PDX (pralatrexate), is a novel antifolate currently under evaluation in a pivotal Phase 2 (PROPEL) trial in patients with relapsed or refractory peripheral T-cell lymphoma. The PROPEL trial is...

Allos Therapeutics Initiates Study of RH1 in Patients with Advanced Solid Tumors or non-Hodgkin's Lymphoma

...and commercialization of small molecule therapeutics for the treatment of cancer. The Company's lead product candidate, PDX (pralatrexate), is a novel antifolate currently under evaluation in a pivotal Phase 2 (PROPEL) trial in patients with relapsed or refractory peripheral T-cell lymphoma. The PROPEL trial is...

BiPar Expands Management Team to Advance Lead PARP Inhibitor Product Candidate Into Phase 2 Trials for Cancer

... to focus solely on oncology assets. He led the licensing effort to acquire both oncology products currently in their portfolio: pralatrexate, a novel antifolate currently in a registration trial in peripheral T-cell lymphoma, and RH1, currently in a Phase 1 trial for solid tumors. Before Allos, Mr. Malek held ...

Studies Suggest Key Correlation Between Lung Cancer Subtype and Treatment Outcomes

... with chemotherapy. J Clin Oncol 2004; 22:1589-97. (3) Sigmond J, Backus HH, Wouters D, et al. Induction of resistance to the multitargeted antifolate pemetrexed (ALIMTA) in WiDr human colon cancer cells is associated with thymidylate synthase overexpression. Biochem Pharmacol 2003; 66:431-...

Interim Response and Safety Analyses Support Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma

...and commercialization of small molecule therapeutics for the treatment of cancer. The Company's lead product candidate, PDX (pralatrexate), is a novel antifolate currently under evaluation in a pivotal Phase 2 trial in patients with relapsed or refractory peripheral T-cell lymphoma. The Company is also investig...

Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma

...ollment in a Phase 1, open-label, multi-center study of the Company's novel antifolate PDX (pralatrexate) with vitamin B12 and folic acid supplementation in patie...ancer. The company's lead product candidate, PDX (pralatrexate), is a novel antifolate currently under evaluation in a pivotal Phase 2 trial in patients with rela...

Hana Biosciences Announces Data to be Presented On Talvesta (Talotrexin) for Injection at The American Association for Cancer Research Annual Meeting

...(tm) (talotrexin) for Injection Talvesta(tm) is a novel nonpolyglutamable antifolate drug under development for the treatment of various types of cancers. Talve...more potency in overcoming polyglutamation, a well-established mechanism of antifolate resistance. Talvesta also binds more tightly to its anti-tumor target DHFR,...
Antifolate in Biological Technology

Allos Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference

...and commercialization of small molecule therapeutics for the treatment of cancer. The Company's lead product candidate, PDX (pralatrexate), is a novel antifolate currently under evaluation in a pivotal Phase 2 (PROPEL) trial in patients with relapsed or refractory peripheral T-cell lymphoma. The PROPEL trial is...

Allos Therapeutics to Present at the 2007 JMP Securities Healthcare Focus Conference

...and commercialization of small molecule therapeutics for the treatment of cancer. The Company's lead product candidate, PDX (pralatrexate), is a novel antifolate currently under evaluation in a pivotal Phase 2 (PROPEL) trial in patients with relapsed or refractory peripheral T-cell lymphoma. The PROPEL trial is...

Three PDX (Pralatrexate) Studies Presented at the 2007 AACR-NCI-EORTC Conference

...n vitro. PDX in NSCLC (Phase 1) The poster entitled "Phase 1 study of the antifolate pralatrexate when given with vitamin B12 and folic acid supplementation in ...ancer. The Company's lead product candidate, PDX (pralatrexate), is a novel antifolate currently under evaluation in a pivotal Phase 2 (PROPEL) trial in patients ...

Allos Therapeutics to Present at the 2007 UBS Global Life Sciences Conference

...and commercialization of small molecule therapeutics for the treatment of cancer. The Company's lead product candidate, PDX (pralatrexate), is a novel antifolate currently under evaluation in a pivotal Phase 2 trial in patients with relapsed or refractory peripheral T-cell lymphoma. The Company is also investig...

Allos Therapeutics to Present at the Bear Stearns 20th Annual Healthcare Conference

...and commercialization of small molecule therapeutics for the treatment of cancer. The Company's lead product candidate, PDX (pralatrexate), is a novel antifolate currently under evaluation in a pivotal Phase 2 trial in patients with relapsed or refractory peripheral T-cell lymphoma. The Company is also investig...
Other Tags
(Date:10/22/2014)... 2014 Medical Solutions , ... happy to announce that our co-founder and CFO, ... Analysts’ Staffing 100 for 2014. Anderson was also ... influential people in the staffing industry,” in 2013.     ... 13th-largest healthcare staffing company in the U.S., was ...
(Date:10/22/2014)... Oct. 21, 2014 (HealthDay News) -- The United ... arriving from Ebola-affected nations of West Africa land ... them for infection with the virus. In ... Johnson noted that 94 percent of air passengers ... at one of these five airports -- New ...
(Date:10/22/2014)... Washington, D.C. (PRWEB) October 22, 2014 With ... November, a national survey by the American Institutes for Research ... they know how to use health insurance, but 42 percent ... review a plan’s details before signing up for coverage. , ... literacy, with only 20 percent able to calculate correctly how ...
(Date:10/22/2014)... 2014 Losing Weight Your Body’s Way , ... you in the face, it certainly can be difficult to ... body an extra favor by doing it the healthy way? ... Instead, listen to your body, exercise regularly, and choose foods ... to losing weight; you need to exercise more and eat ...
(Date:10/22/2014)... October 22, 2014 Akeso Biomedical, ... for the treatment of bacterial infections, microbial biofilms, and ... joined its board of directors. , Dr. ... Systems at The Massachusetts Institute of Technology, or MIT. ... since 1968. Dr. Sinskey also holds positions as Co-Director ...
Breaking Medicine News(10 mins):Health News:Medical Solutions Co-Founder/CFO Scott Anderson Named to Staffing Industry Analysts’ 2014 Staffing 100 2Health News:Medical Solutions Co-Founder/CFO Scott Anderson Named to Staffing Industry Analysts’ 2014 Staffing 100 3Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 2Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 3Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 2Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 3Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 4Health News:ReductionGuruMD Presents Ways to Improve Your Weight Loss Results 2Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2
(Date:10/22/2014)... -- Aware, Inc. (NASDAQ: AWRE ), a leading ... for its third quarter ended September 30, 2014. ... an increase of 40% compared to $4.3 million in the ... of 2014 was $4.1 million compared to $1.0 million in ... current three month period was primarily due to: i) a ...
(Date:10/18/2014)... a group of 2,000 patients referred for evaluation ... potential molecular diagnosis for 25 percent, including detection ... new mutations contributing to disease, according to a ... is being released to coincide with the American ... sequencing analyzes the exons or coding regions of ...
(Date:10/17/2014)... . Why do ... to reproduce? And why are there two sexes anyway? These ... of the research journal Molecular Human Reproduction published ... Bielefeld University Bielefeld has compiled this special issue on sperm ... to copulate with several males in quick succession – chimpanzees ...
Breaking Biology News(10 mins):Aware, Inc. Reports Third Quarter 2014 Financial Results 2Aware, Inc. Reports Third Quarter 2014 Financial Results 3Aware, Inc. Reports Third Quarter 2014 Financial Results 4Aware, Inc. Reports Third Quarter 2014 Financial Results 5Aware, Inc. Reports Third Quarter 2014 Financial Results 6Aware, Inc. Reports Third Quarter 2014 Financial Results 7Whole-exome sequencing shows potential as diagnostic tool 2Sperm wars 2
Other Contents